Yahel Hacohen (United Kingdom)
University College London Queen Square Institute of Neurology Faculty of Brain SciencesAuthor Of 1 Presentation
INTERNATIONAL MAGNIMS-CMSC-NAIMS CONSENSUS RECOMMENDATIONS ON THE USE OF STANDARDIZED MRI IN MS
- Massimo Filippi (Italy)
Abstract
Background and Aims:
Standardized MRI guidelines published in 2015 by the MAGNIMS group and in 2016 by the CMSC are important for the diagnosis and monitoring of multiple sclerosis (MS) patients. We present the international consensus 2021 revisions of the guidelines on MRI in MS, which merge recommendations from MAGNIMS, CMSC, and NAIMS.
Methods:
Two panels of experts convened to update existing guidelines. One panel convened in Graz, Austria to update MAGNIMS guidelines. A second panel met separately and independently in Newark, USA to update CMSC guidelines and discuss advocacy efforts. The leadership of the MAGNIMS, NAIMS, and CMSC working groups combined their efforts to reach an international consensus.
Results:
The revised guidelines on MRI in MS merges recommendations from MAGNIMS, CMSC, and NAIMS to improve the use of MRI for diagnosis, prognosis and monitoring of MS patients. 3D acquisitions are emphasized for optimal comparison over time. Core brain sequences include a 3D-T2wFLAIR for lesion identification and monitoring treatment effectiveness. Gadolinium-based contrast is recommended for diagnostic studies and judicious use for routine monitoring of MS patients. Additional DWI sequences are recommended for PML safety monitoring. Optional sequences that could be incorporated into future recommendations include high resolution 3D-T1w for brain atrophy monitoring; DIR/PSIR for identifying cortical lesions; and SWI for the central vein sign evaluation.
Conclusions:
Dissemination of the 2021 evidence-based MAGNIMS-CMSC-NAIMS international consensus guidelines through congresses would be a welcome addition to the advocacy efforts in promoting the use of standardized MRI in diagnosis and follow-up of MS patients.